Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
Alimera Sciences (Nasdaq: ALIM), a leader in ophthalmology treatments, announces that President and CEO Rick Eiswirth will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences (Nasdaq: ALIM), a leader in ophthalmology treatments, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available for on-demand listening from 6:00 AM ET on January 11 until the end of business on January 14, 2021. Registration for the presentation can be accessed online. Alimera focuses on developing treatments for retinal diseases, addressing unmet needs in an aging population.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was +5.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.
The presentation will be available for on-demand listening beginning at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021. For those interested in viewing Mr. Eiswirth’s presentation, registration can be accessed here.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.